journal article·2014-01

Evaluation of Montmorillonite/Poly (L-Lactide) microcomposite spheres as ambidextrous reservoirs for controlled release of Capecitabine (Xeloda) and assessment of cell cytotoxic and oxidative stress markers

Bhavesh D. Kevadiya, Shiva Shankaran Chettiar, Shalini Rajkumar, Hari C. Bajaj, Harshad Brahmbhatt, Jayesh C. Chaudhari, Rahul P. Thumbar, Devendrasinh Jhala, Mandava V. Rao

Publisher page

Abstract

Abstract This work evaluates cationic intercalation of Capecitabine (Xeloda), an antineoplastic agent in interlayer gallery of Na + -MMT, which was further compounded with Poly ( L -Lactide) to form microcomposite spheres, for oral chemotherapy of breast cancer. The XRD, TGA, SEM, TEM and FT-IR analysis indicated the CAP intercalated in interlayer of MMT and stabilized in the longitudinal monolayer mode by electrostatic interface. No significant alteration in fundamental active properties of CAP was found in the MMT efficacy and data from in vitro study showed controlled drug release pattern >72 h. The efficacy of CAP-MMT hybrid/MPs was also confirmed on Human neuroblastoma cell line (IMR32) by in vitro cell culture experiments evaluating cell cytotoxic and oxidative stress marker indices which showed that intercalated drug and MPs, were as effective as pristine drug. In vivo pharmacokinetics of CAP-MMT hybrids in rats was examined and plasma CAP levels were evaluated. Our findings suggest that CAP-MMT hybrids and MPs can be of considerable value in chemotherapy of malignant neoplastic disease with reduced side effects and clearly demonstrated that MMT not only plays a role as a delivery matrix for drug but also facilitates significant increase in the delivery proficiency.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: biodegradable polymer synthesis and properties · Graphene and Nanomaterials Applications · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (31)

Show source-provided references
1. 5-Fluorouracil-induced coronary vasospasm10.1177/107327480401100107 ↗
2. Clinical pharmacology of 5-fluorouracil10.2165/00003088-198916040-00002 ↗
3. Layered inorganic nanocomposites: a promising carrier for 5-fluorouracil (5-FU)10.1016/j.ejpb.2012.01.004 ↗
4. Preparation of 5-fluorouracil/β-cyclodextrin complex intercalated in layered double hydroxide and the controlled drug release properties10.1021/ie100990z ↗
5. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer10.1021/cr900028p ↗
6. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts10.1016/S0006-2952(97)00682-5 ↗
7. Design of a novel oral fluoropyrimidine carbamate, apecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue10.1016/S0959-8049(98)00058-6 ↗
8. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients10.1007/s002800050043 ↗
9. Capecitabine in the management of colorectal cancer
10. Capecitabine for locally advanced and metastatic colorectal cancer: a review10.4251/wjgo.v2.i8.311 ↗
11. Capecitabine: a review10.1016/j.clinthera.2005.01.005 ↗
12. Controlled release of donepezil intercalated in smectite clays10.1016/j.ijpharm.2008.04.012 ↗
13. Multifunctional poly (D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer10.1016/j.biomaterials.2007.09.038 ↗
14. Poly (D,L -lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs10.1016/j.biomaterials.2005.03.021 ↗
15. Poly(lactide)–vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel10.1016/j.biomaterials.2009.02.045 ↗
16. Layered bionanocomposites as carrier for procainamide10.1016/j.ijpharm.2010.01.002 ↗
17. Confinement and controlled release of quinine on chitosan–montmorillonite bionanocomposites10.1002/pola.25046 ↗
18. Design and evaluation of controlled drug delivery system of buspirone using inorganic layered clay mineral10.1016/j.micromeso.2010.04.003 ↗
19. A protein kinase Cβ inhibitor attenuates multidrug resistance of neuroblastoma cells
20. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays10.1016/0022-1759(83)90303-4 ↗
21. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction10.1016/0003-2697(79)90738-3 ↗
22. A modified spectrophotometric assay of superoxide dismutase
23. Estimation of total protein-bound and non-protein sulphydryl groups in tissue with Ellman’s reagent10.1016/0003-2697(68)90092-4 ↗
24. Determination of carbonyl groups in oxidized proteins
25. Development of validated stability indicating RP-HPLC Method for the estimation of capecitabine in pure and pharmaceutical formulations
26. Determination of the thermodynamic dissociation constant of capecitabine using spectrophotometric and potentiometric titration data10.1016/j.jct.2011.01.012 ↗
27. Novel interpenetrating network chitosan-poly(ethylene oxide-g-acrylamide) hydrogel microspheres for the controlled release of capecitabine10.1016/j.ijpharm.2006.05.061 ↗
28. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction10.1016/j.bbagen.2005.10.012 ↗
29. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir10.1093/jnci/djj049 ↗
30. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness10.1177/1534735404270335 ↗
31. Oxidative stress mediates through apoptosis the anticancer effect of phospho-nonsteroidal anti-inflammatory drugs: implications for the role of oxidative stress in the action of anticancer agents10.1124/jpet.111.183533 ↗